Blog

  • Arbuthnot lending declines on uncertainty but wealth management strong

    (Alliance News) – Arbuthnot Banking Group PLC on Thursday reported a decline in customer loans and leased assets at the end of the third quarter, with budget uncertainty weighing on sentiment.

    The London-based merchant bank reported GBP2.3 billion in customer loans and lease assets at September 30, down 9% from GBP2.5 billion a year earlier.

    Lending fell by 12% on-year to GBP1.4 billion, and was down 3% from the second quarter.

    Arbuthnot emphasised the importance of residential investment and private equity for its business, with both markets hit by lower confidence among businesses and households. The bank attributed the uncertain mood to “speculation around the autumn budget where various tax increases are being suggested”.

    “The uncertain economic outlook has meant that lending markets have continued to observe thin volumes of business with lenders aggressively competing for transactions by offering low rates,” Arbuthnot added, but maintained it “has not been drawn into this competition.”

    Still, the bank reported 24% annual growth in funds under management and administration, which amounted to GBP2.5 billion at the end of September, compared to GBP2.0 billion a year prior. This was “driven by strong inflows year to date and investment portfolio performance following the market turbulence at the beginning of the year,” Arbuthnot said. FUMA grew 5% on-quarter.

    In addition, customer deposit balances rose 17% on-year to GBP4.4 billion from GBP3.8 billion, but remained flat on a quarterly basis.

    Looking ahead, Arbuthnot expects “continuing macro-economic uncertainty,” and plans to “focus on continuing to support existing clients, whilst maintaining its principle of high quality credit lending for new business.”

    Arbuthnot Banking shares traded 0.4% higher at 901.00 pence on Thursday afternoon in London.

    By Holly Munks, Alliance News reporter

    Comments and questions to newsroom@alliancenews.com

    Copyright 2025 Alliance News Ltd. All Rights Reserved.

    Continue Reading

  • How ‘Nobody Wants This’ Got Selena Gomez, Chris Stapleton for Season 2

    How ‘Nobody Wants This’ Got Selena Gomez, Chris Stapleton for Season 2

    Nobody Wants This returns to the screen on Thursday on Netflix as one of the most anticipated shows of the year, and now it’s got an original soundtrack that matches those ambitions.

    A cross-genre mishmash that includes pop from the…

    Continue Reading

  • No reduction in Gaza hunger since truce: WHO – Al Arabiya English

    1. No reduction in Gaza hunger since truce: WHO  Al Arabiya English
    2. Gaza health crisis will last for ‘generations’, WHO chief warns  BBC
    3. Hunger crisis in Gaza is ‘catastrophic’ despite ceasefire, WHO chief says  Al Jazeera
    4. 50 Palestinian patients…

    Continue Reading

  • Strategist Selection – What’s the best line-up for the Mexico City Grand Prix?

    Strategist Selection – What’s the best line-up for the Mexico City Grand Prix?

    After a thrilling stop in Austin, Formula 1 stays in the Americas for another fan-favourite – the Mexico City Grand Prix. Famous for its high-altitude conditions that challenge engines, brakes, and tyre management, who is poised to make the…

    Continue Reading

  • Ipsen Acquires ImCheck Therapeutics: A&O Shearman Advises Deal

    Ipsen Acquires ImCheck Therapeutics: A&O Shearman Advises Deal

    This acquisition is focused on the clinical-stage program ICT01 in acute myeloid leukemia (AML) targeting patients who are ineligible for intensive chemotherapy or targeted treatments. ICT01 is a first-in-class monoclonal antibody whose data from an ongoing trial showed a high treatment response, which could make it a new standard of care for acute myeloid leukemia, an aggressive blood cancer affecting older adults.

    The transaction is expected to close by the end of Q1 2026, subject to fulfilment of customary closing conditions, including the required regulatory and governmental approvals under French and U.S. regulations.

    Marc Castagnède, partner at A&O Shearman, said: “This transaction clearly demonstrates our ability to support clients in executing complex, strategic deals in highly specialized sectors such as life sciences. We are proud to have advised Ipsen on this landmark acquisition, which sits at the heart of biotech innovation and therapeutic advancement.”

    The A&O Shearman team is being led by M&A partner Marc Castagnède with support from M&A senior associate Antoine Messent, and associate Fatima Ahamada.

    Other members of the Paris team involved in the transaction include partner Olivier Picquerey and senior associate Antoine Tantaro on employment matters; partners Laëtitia Bénard and Charles Tuffreau, associate Manon Perret and consultant Marianne Delassaussé on IP matters; senior associate Clémence d’Almeida on antitrust matters; counsel Luc Lamblin and associate Charles-Hugo Lerebour on regulatory and FDI matters; partner Laurie-Anne Ancenys and associate Thomas Feigean on IT and data aspects; and partner Charles del Valle on tax matters.

    Support was also provided by the A&O Shearman US corporate and antitrust teams.

    Continue Reading

  • 1886 Evolves Into Urban Luxury at Riyadh Fashion Week Fall 2025

    1886 Evolves Into Urban Luxury at Riyadh Fashion Week Fall 2025

    Nicolas Ottersten, creative director of Saudi’s popular streetwear label 1886, presented a collection that crystallized the brand’s evolution from its street roots into what he’s dubbed “urban luxury.” It’s a synthesis of…

    Continue Reading

  • Impaired movement of cerebrospinal fluid predicts dementia risk later in life

    Impaired movement of cerebrospinal fluid predicts dementia risk later in life

    Problems with the brain’s waste clearance system could underlie many cases of dementia and help explain why poor sleep patterns and cardiovascular risk factors such as high blood pressure increase the risk of dementia.

    A study led…

    Continue Reading

  • Double Down: Orlando Pride playoff tickets available as 2024 NWSL Champions Look to defend title

    Double Down: Orlando Pride playoff tickets available as 2024 NWSL Champions Look to defend title

    ORLANDO, Fla. (Oct. 23, 2025) — Orlando Pride (11-8-6, 39 points) today announced that tickets for its potential quarterfinals round home match in the 2025 NWSL Playoffs, presented by Google Pixel, will go on sale…

    Continue Reading

  • Brain’s circHomer1 RNA offers insights for future neurological treatments

    Brain’s circHomer1 RNA offers insights for future neurological treatments

    A circular RNA called circHomer1 has been found to play a vital role in forming and adjusting synapses in developing mouse brains, revealing an overlooked mechanism that helps visual neurons respond to changes in sensory input.